{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:19Z","timestamp":1787021239812,"version":"build-2736575974"},"reference-count":51,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (&amp;gt;\u200515\u2005000\u2005000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N\u2005=\u20051971), monoclonal antibodies (N\u2005=\u20051644, of which N\u2005=\u20051330 were associated with immune checkpoint inhibitors\u2014ICIs), hormone therapy (N\u2005=\u2005291), anti-infectives (N\u2005=\u2005252), drugs for hypercortisolism or adrenocortical cancer diagnosis\/treatment (N\u2005=\u2005169), and protein kinase inhibitors (N\u2005=\u2005138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac359","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T13:26:52Z","timestamp":1655299612000},"page":"e3107-e3114","source":"Crossref","is-referenced-by-count":16,"title":["The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1210","volume":"107","author":[{"given":"Emanuel","family":"Raschi","sequence":"first","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum\u2013University of Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum\u2013University of Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-3631","authenticated-orcid":false,"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Repaci","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna , Bologna 40138 , Italy"},{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum\u2013University of Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum\u2013University of Bologna , Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna , Bologna 40138 , Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2013University of Bologna, Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-8906","authenticated-orcid":false,"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna , Bologna 40138 , Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2013University of Bologna, Bologna 40138 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"issue":"12","key":"2022071417245941300_CIT0001","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/jama.1952.03680120058012","article-title":"Iatrogenic adrenal insufficiency","volume":"150","year":"1952","journal-title":"J Am Med Assoc."},{"issue":"10","key":"2022071417245941300_CIT0002","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41574-019-0248-9","article-title":"Novel medications inducing adrenal insufficiency","volume":"15","author":"Bornstein","year":"2019","journal-title":"Nat Rev Endocrinol."},{"issue":"8","key":"2022071417245941300_CIT0003","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist."},{"issue":"4","key":"2022071417245941300_CIT0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol."},{"issue":"12","key":"2022071417245941300_CIT0005","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/pds.4672","article-title":"Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA","volume":"27","author":"Fukazawa","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2022071417245941300_CIT0006","article-title":"The changing face of drug-induced adrenal insufficiency in the Food and Drug Administration Adverse Event Reporting System.\u201d","author":"Raschi","journal-title":"Supplementary data for"},{"issue":"2","key":"2022071417245941300_CIT0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie."},{"issue":"6","key":"2022071417245941300_CIT0008","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"3","key":"2022071417245941300_CIT0009","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjd.19677","article-title":"The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice","volume":"184","author":"Raschi","year":"2021","journal-title":"Br J Dermatol."},{"issue":"7","key":"2022071417245941300_CIT0010","doi-asserted-by":"crossref","first-page":"e015905","DOI":"10.1136\/bmjopen-2017-015905","article-title":"Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France","volume":"7","author":"B\u00e9nard-Laribi\u00e8re","year":"2017","journal-title":"BMJ Open."},{"issue":"11","key":"2022071417245941300_CIT0011","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1093\/rheumatology\/ker017","article-title":"Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years","volume":"50","author":"Fardet","year":"2011","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"2022071417245941300_CIT0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/EJE-19-0305","article-title":"Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark","volume":"181","author":"Laugesen","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022071417245941300_CIT0013","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1530\/EJE-15-0608","article-title":"Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol","volume":"173","author":"Woods","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"9935","key":"2022071417245941300_CIT0014","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet."},{"issue":"4","key":"2022071417245941300_CIT0015","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-20-1199","article-title":"Management of endocrine disease: glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?","volume":"184","author":"Laugesen","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"2022071417245941300_CIT0016","doi-asserted-by":"crossref","first-page":"n1380","DOI":"10.1136\/bmj.n1380","article-title":"Glucocorticoid induced adrenal insufficiency","volume":"374","author":"Prete","year":"2021","journal-title":"BMJ."},{"issue":"6","key":"2022071417245941300_CIT0017","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","article-title":"Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis","volume":"100","author":"Broersen","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022071417245941300_CIT0018","doi-asserted-by":"crossref","first-page":"e0212259","DOI":"10.1371\/journal.pone.0212259","article-title":"Clinical indicators of adrenal insufficiency following discontinuation of oral glucocorticoid therapy: a Danish population-based self-controlled case series analysis","volume":"14","author":"Laugesen","year":"2019","journal-title":"PLoS One."},{"issue":"4","key":"2022071417245941300_CIT0019","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/er.2001-0014","article-title":"Endocrine withdrawal syndromes","volume":"24","author":"Hochberg","year":"2003","journal-title":"Endocr Rev."},{"issue":"4","key":"2022071417245941300_CIT0020","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1210\/jc.2014-3632","article-title":"Time to recovery of adrenal function after curative surgery for Cushing\u2019s syndrome depends on etiology","volume":"100","author":"Berr","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022071417245941300_CIT0021","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1210\/jc.2014-1401","article-title":"Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing\u2019s syndrome: a systematic review of the literature","volume":"99","author":"Di Dalmazi","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022071417245941300_CIT0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semarthrit.2016.03.001","article-title":"Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review","volume":"46","author":"Joseph","year":"2016","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"2022071417245941300_CIT0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cen.12865","article-title":"Incidence of adrenal crisis in patients with adrenal insufficiency","volume":"84","author":"Smans","year":"2016","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7","key":"2022071417245941300_CIT0024","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol."},{"issue":"2","key":"2022071417245941300_CIT0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"2","key":"2022071417245941300_CIT0026","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol."},{"issue":"12","key":"2022071417245941300_CIT0027","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"3","key":"2022071417245941300_CIT0028","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022071417245941300_CIT0029","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"issue":"2","key":"2022071417245941300_CIT0030","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer."},{"key":"2022071417245941300_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol."},{"key":"2022071417245941300_CIT0032","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison\u2019s disease: a rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur J Cancer."},{"issue":"6","key":"2022071417245941300_CIT0033","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc."},{"issue":"11","key":"2022071417245941300_CIT0034","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med."},{"key":"2022071417245941300_CIT0035","first-page":"1-4","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"issue":"5","key":"2022071417245941300_CIT0036","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open."},{"key":"2022071417245941300_CIT0037","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejca.2021.08.038","article-title":"Anti-angiogenic agent-associated adrenal insufficiency in immune checkpoint inhibitors-treated patients","volume":"157","author":"Guo","year":"2021","journal-title":"Eur J Cancer."},{"issue":"3","key":"2022071417245941300_CIT0038","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2018-01836","article-title":"Primary adrenal insufficiency during lenvatinib or vandetanib and improvement of fatigue after cortisone acetate therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022071417245941300_CIT0039","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrendo.2014.114","article-title":"VEGF-targeted cancer therapeutics\u2014paradoxical effects in endocrine organs","volume":"10","author":"Cao","year":"2014","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"2022071417245941300_CIT0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"36","key":"2022071417245941300_CIT0041","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022071417245941300_CIT0042","doi-asserted-by":"crossref","first-page":"e230760","DOI":"10.1136\/bcr-2019-230760","article-title":"Type II polyglandular autoimmune syndrome: a case of Addison\u2019s disease precipitated by use of levothyroxine","volume":"12","author":"Hoener","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"8","key":"2022071417245941300_CIT0043","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs."},{"issue":"9","key":"2022071417245941300_CIT0044","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hiv.12039","article-title":"Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management","volume":"14","author":"Saberi","year":"2013","journal-title":"HIV Med."},{"issue":"6","key":"2022071417245941300_CIT0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17446651.2021.1979393","article-title":"Adrenal insufficiency in HIV\/AIDS: a review","volume":"16","author":"Mifsud","year":"2021","journal-title":"Expert Rev Endocrinol Metab."},{"issue":"11","key":"2022071417245941300_CIT0046","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP-2020-0297","article-title":"Clinical presentation and outcomes of opioid-induced adrenal insufficiency","volume":"26","author":"Li","year":"2020","journal-title":"Endocr Pract."},{"key":"2022071417245941300_CIT0047","first-page":"1178221820930006","article-title":"Misuse of tramadol in the United States: an analysis of the National Survey of Drug Use and Health 2002-2017","volume":"14","author":"Reines","year":"2020","journal-title":"Subst Abuse."},{"issue":"5","key":"2022071417245941300_CIT0048","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc1414161","article-title":"Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages","volume":"372","author":"Warkentin","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"2022071417245941300_CIT0049","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00198-018-4508-7","article-title":"Adrenal crisis after first infusion of zoledronic acid: a case report","volume":"29","author":"Smrecnik","year":"2018","journal-title":"Osteoporos Int."},{"issue":"11","key":"2022071417245941300_CIT0050","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"issue":"4","key":"2022071417245941300_CIT0051","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac359\/44249433\/dgac359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3107\/44886647\/dgac359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3107\/44886647\/dgac359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:36:12Z","timestamp":1657805772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/8\/e3107\/6608931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,15]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac359","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,15]]}}}